# Frederick Jones

> Frederick Jones is a debt financing investor at BioAdvance backing Biotechnology and Health Care. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [BioAdvance](https://shizune.co/investors/profile/bioadvance)
- Location: Boston, United States
- Total investments: 5
- Last investment: Apr 2016
- Lead investor: 20%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/frederick-rick-jones-a82310a

Frederick Jones is a debt financing investor at BioAdvance in Boston focused on Biotechnology and Health Care. Frederick Jones is the Partner at BioAdvance. Frederick attended the University of Pennsylvania.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 80% |
| Health Care | 3 | 60% |
| Medical | 2 | 40% |
| Therapeutics | 2 | 40% |
| Pharmaceutical | 2 | 40% |

10 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Debt Financing | 2 | 40% |
| Seed | 1 | 20% |
| Series B | 1 | 20% |
| Series C | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Aeromics | Aeromics is a clinical candidate targeting a molecular water channel for the treatment of cerebral edema in stroke.A paradigm shift in its understanding of water physiology was the discovery aquaporins, proteins that form water channels to allow water into and out of cells, by Peter Agre (2003 Nobel Prize in Chemistry). Despite the vital role ofaquaporins in maintaining water homeostasis and its implications in various disease states, therapeutic agents targeting aquaporins have until now remained elusive.Aeromics’ drug candidate, AER-271, targets aquaporin-4 (AQP4), the primary water channel in the brain, and has best-in-class credentials for acute intravenous therapy for stroke-related cerebral edema (CE). |  | Debt Financing | Apr 15, 2016 |  |
| Ischemia Care | Ischemia Care operates as an artificial intelligence company specializing in diagnostic blood tests for stroke and atrial fibrillation. It utilizes blood testing for stroke patients as a clinical workflow tool to improve patient outcomes and reduce hospital costs, by empowering clinicians with new information. A simple blood test for cause couldstratify patients by cause to ensure the appropriate treatment pathways are adopted to prevent recurrence, resulting in better outcomes.Ischemia Care was established in 2009 and is headquartered in Oxford, Ohio, United States. |  | Series C | Oct 13, 2014 |  |
| ZZ Biotech | ZZ Biotech LLC is a clinical stage company developing innovative biologic treatments for ischemic stroke. ZZ Biotech was formed in 2006 to focus on the development of 3K3A-APC, a novel second-generation variant of a naturally occurring human protein, activated Protein C (APC). The major unwanted side effect of APC is bleeding, which limits itspharmacologic dosing in man. 3K3A-APC has markedly reduced anticoagulant activity, but preserved cell-protective and anti-inflammatory activities compared to wild-type APC. In animal models of stroke 3K3A-APC has shown an advantage over wild-type APC in enhanced efficacy and reduced risk for bleeding. Additionally, the combination of 3K3A-APC and tissue Plasminogen Activator (tPA) provides benefits well beyond those found with either agent alone. ZZ Biotech is currently recruiting patients in a multicenter Phase 2 clinical trial of 3K3A-APC in patients suffering from acute ischemic stroke. The study is being supported by the National Institutes of Health through a pair of NeuroNEXT grants. The Phase 2 study is to evaluate safety, tolerability and activity of ZZ Biotech’s 3K3A-APC when given after tissue plasminogen activator (tPA), mechanical thrombectomy, or both, in patients who have experienced moderate to severe ischemic stroke. |  | Seed | Mar 13, 2014 |  |
| Remedy Pharmaceuticals | Remedy Pharmaceuticals, Inc. develops small molecule drugs that target NCCa-ATP channels in acute central nervous system injuries, including traumatic brain injuries, strokes, and spinal cord injuries. Its RP-1127 is an intravenous version of glyburide, an inhibitor of NCCa-ATP channels that acts through antagonism of the type-1 sulfonylureareceptor. The company was founded in 2004 and is based in New York, New York. |  | Series B | Feb 26, 2014 |  |
| Aggamin Biologics | Aggamin is an early-stage biotechnology company founded in early 2010 to develop and commercialize therapies for a variety of vascular diseases. The lead program is focused on preeclampsia — a currently untreatable disease affecting 5% of pregnancies with an annual cost to the U.S health care system of $10 billion. Lead product is an extracorporealdevice for preeclampsia that reduces circulating pathogenic proteins to improve maternal and fetal health. The company objectives are to manufacture and commercialize the preeclampsia device as a safe first-in-class treatment for preeclampsia that will control maternal symptoms and extend pregnancy, thus improving both maternal and neonatal outcomes. |  | Debt Financing | Oct 20, 2011 |  |

5 of 5 investments shown.

## Co-investors
- [National Institutes of Health](https://shizune.co/investors/profile/national-institutes-of-health) — VC Fund, 1 deal together

## About BioAdvance

VC Fund · Philadelphia, United States

BioAdvance provides funding to startup life sciences companies in Southeastern Pennsylvania through its new $50 million Greenhouse Fund. They invest in therapeutics, devices, diagnostics and platform technologies focused on human health.Since its first investments in 2003, BioAdvance has become one of the nation's leading investorsproviding pre-seed and seed-stage funding. To date they have committed more than $40 million to more than 50 seed-stage companies and 17 pre-seed companies. Their portfolio companies are working to develop products to treat health problems including Alzheimer's disease, cancer, obesity, GI disorders, neurological and respiratory illnesses. BioAdvance was established with $33 million from the Commonwealth of Pennsylvania's share of tobacco settlement monies.

5 contacts available at BioAdvance.

| Name | Title | Profile |
| --- | --- | --- |
| Shahram Hejazi | Partner | https://shizune.co/investors/profile/shahram-hejazi |
| Barbara S. Schilberg | Managing Director | https://shizune.co/investors/profile/barbara-s-schilberg |
| Frederick Jones | Partner | https://shizune.co/investors/profile/frederick-jones |
| Gregory Harriman | Partner and Chief Investment Officer | https://shizune.co/investors/profile/gregory-harriman |
| Jeff Edelson | Entrepreneur in Residence / Scientific Liason | https://shizune.co/investors/profile/jeff-edelson |

## Similar investors

### Similar stage
- [ENISA](https://shizune.co/investors/profile/enisa-2) — VC Fund
- [Development Bank of Wales](https://shizune.co/investors/profile/development-bank-of-wales) — VC Fund
- [The FSE Group](https://shizune.co/investors/profile/finance-south-east) — VC Fund

## FAQ

### What does Frederick Jones invest in?

Frederick Jones invests primarily in Biotechnology, Health Care and Medical startups, most often at Debt Financing and Seed stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Frederick Jones last invest?

The most recent investment recorded for Frederick Jones closed in Apr 2016. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co